Introduction
Inter-individual variability of pharmacokinetics and pharmacodynamics of anticancer drugs constitutes a major limitation to their clinical use. Drug metabolizing enzymes and membrane transporters of these agents affect their in vivo disposition, and polymorphisms of these genes may influence function and explain some of the inter-individual variability. [1] [2] [3] [4] [5] [6] [7] Commonly used cytotoxics such as docetaxel and doxorubicin have narrow therapeutic indices and significant inter-individual variations in drug disposition. Both drugs are effluxed from cells expressing ABCB1 and metabolized mainly in the liver, with CYP3A being the main metabolizing enzyme of docetaxel. Common ABCB1 polymorphisms have not been definitively shown to affect doxorubicin disposition. Among the known CYP3A4 and CYP3A5 polymorphisms, CYP3A4*1B and CYP3A5*3 are common and have potential functional significance. The CYP3A4*1B, a promoter polymorphism commonly found in the African-American population, is absent or rare in our Asian population. On the other hand, the CYP3A5*3 splice site variant that causes loss of hepatic expression of CYP3A5 is common, but does not account for inter-individual variability of docetaxel disposition in our Asian population. 8 Pregnane X receptor (PXR), constitutive androstane receptor (CAR) and hepatocyte nuclear factor-4a (HNF4a) are orphan nuclear receptors that regulate transcription of multiple cytochrome P450 enzymes and transporters, including ABCB1 and BCRP (ABCG2), and are activated by ligand binding. [9] [10] [11] [12] [13] [14] Numerous ligands may bind to these receptors, including xenobiotics, that is, drugs like rifampicin, and herbal compounds like St John's Wort. Upon activation by xenobiotics via ligand binding, the receptors heterodimerize with retinoid X receptor (RXR) and bind to specific response elements in the regulatory regions of drug metabolizing enzymes and transporters, inducing their expression and, therefore, serving as an endogenous xenobiotic protective mechanism. 11, 13, 15, 16 Functionally deficient variants of orphan nuclear receptors can conceivably influence the baseline expression and activity of numerous drug metabolizing enzymes and transporters, in particular CYP3A and ABCB1, and contribute to their inter-individual variability. 17, 18 We postulate further that inter-ethnic patterns of genetic polymorphisms of these receptors may account for variation in pharmacokinetics and pharmacodynamics of drugs between the races. There is currently no clinical data correlating orphan nuclear receptor genetic variants with chemotherapy disposition. As such, we comprehensively sequenced the exons and splice-site junctions of PXR, CAR and HNF4a to identify and correlate polymorphisms with the pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in our multi-ethnic Asian population.
Results
One hundred and one female breast cancer patients were studied, including 66 Chinese, 26 Malay, 7 Indian and 2 of other ethnic origins. The mean age of the study population was 49.5710 years, and the patient characteristics are listed in Table 1 . Docetaxel and doxorubicin pharmacokinetics and hematologic toxicities after one cycle of chemotherapy for the entire cohort are summarized in Table 2 . The pharmacokinetics of both drugs are similar to that reported in the literature. 19, 20 Comprehensive sequencing of the PXR, CAR and HNF4a genes and CYP3A5*3 genotyping in breast cancer patients A total of four genetic variants were identified by comprehensive sequencing of the three nuclear receptors, PXR, CAR and HNF4a, including two non-synonymous coding region variants in the HNF4a gene, a 5 0 -untranslated region (UTR) variant in the PXR gene, and a silent coding region variant in the CAR gene. The frequencies of the four nuclear receptor genetic variants and CYP3A5*3 are summarized in Table 3 according to ethnic groups. Indians have higher frequency of the PXR 5 0 -UTR variant compared to Chinese and Malays, while there was no statistically significant difference in genotype distribution of the CAR Pro180Pro, HNF4a Met49Val, HNF4a Thr130Ile and CYP3A5*3 variants between the three major ethnic groups. The genotype distribution of all five variants conformed to the HardyWeinberg equilibrium.
Pharmacokinetics correlations
No significant correlations were observed between ethnic group or the presence or absence of each of the four nuclear receptor genetic variants and CYP3A5*3 with docetaxel or doxorubicin clearance, maximum drug concentration (C max ), area under the curve (AUC) and half-life (T 1/2 ).
Pharmacodynamic correlations
Ethnicity and the presence or absence of each of the four nuclear receptor genetic variants and CYP3A5*3 were evaluated for correlation with degree of myelosuppression following one cycle of docetaxel or doxorubicin. Indians and Chinese experienced greater degree of docetaxelinduced leukopenia compared to Malays. In contrast, Chinese experienced greater degree of doxorubicin-induced leucopenia and neutropenia than Malays and Indians (Table  4) .
Patients carrying the HNF4a Met49Val variant had slower recovery of day 15 neutrophil count following the docetaxel administration compared to those with the wild-type variant, with those homozygous for the variant having the lowest counts (percentage day 15 neutrophil difference from baseline were À677285, 2783 and 35762% for wild-type, heterozygotes and homozygotes, respectively, ANOVA, P ¼ 0.046; post hoc Dunnett's test, P ¼ 0.025 for wild type versus homozygote). There was no correlation between the other three nuclear receptor genetic variants or CYP3A5*3 with docetaxel-or doxorubicin-induced myelosuppression. No statistically significant difference was observed between the rate of febrile neutropenia and tumor reduction after one cycle of either drug between patients with different genotypes.
Exploratory analysis was performed for interactions between genetic variants and doxorubicin and docetaxel pharmacokinetic and pharmacodynamic parameters. Interactions were observed between HNF4a Met49Val and CAR Pro180Pro, with patients who were wild type for both variants experiencing least docetaxel-induced neutropenia (percentage nadir neutrophil difference from baseline were 83712, 9476 and 9477% for HNF4a Met49Val wild type Table 3 Frequencies of HNF4a, PXR, CAR and CYP3A5*3 genetic variants in breast cancer patients (n ¼ 101) (n ¼ 5), heterozygote (n ¼ 12) and homozygote (n ¼ 9), respectively, ANOVA, P ¼ 0.030; post hoc Dunnett's test, P ¼ 0.021 and 0.037 for wild type versus heterozygote and wild type versus homozygote, respectively; Figure 1 ). No other significant genotypic associations with pharmacokinetics or pharmacodynamics of either drug were found.
Determination of the frequencies of PXR, CAR and HNF4a variants in the cancer-free population The population frequencies of the four nuclear receptor genetic variants identified in the breast cancer patients were determined by studying 287 cancer-free controls, including 103 Chinese, 111 Malay and 73 Indian. The frequencies of the variants are summarized in Table 5 according to the Figure 1 Box plot comparing docetaxel-induced nadir neutropenia among patients who were wild type for CAR Pro180Pro but with different genotypes for HNF4a Met49Val (ANOVA, P ¼ 0.030; post hoc Dunnett's test, P ¼ 0.021 and 0.037 for wild type versus heterozygote and wild type versus homozygote, respectively). ethnic group. As was observed in the breast cancer patients, the frequency of the PXR 5 0 -UTR variant was higher in Indians. In addition, there was a trend of Indians having higher frequency of the HNF4a Met49Val variant compared to Chinese and Malays in this larger data set. In contrast, Chinese and Malays have very similar distributions of all four genetic variants.
Discussion
We found significant inter-individual variation in docetaxel and doxorubicin pharmacokinetics and pharmacodynamics, as well as significant inter-ethnic differences in docetaxeland doxorubicin-induced myelosuppression in our Asian population comprising three major ethnic groups. However, comprehensive genetic analysis of three major orphan nuclear receptors that influenced the transcription of the key metabolizing enzymes and transporters of these chemotherapeutic agents did not yield an obvious cause that may account for these differences.
PXR and CAR perform crucial protective functions against harmful ligands. Therefore, it is not surprising that very few polymorphisms were detected in our study patients. Nonetheless, we found several previously reported genetic variants in our multi-ethnic Asian population. Given that these nuclear receptors regulate a large number of drug metabolizing enzymes and membrane transporters, functional genetic variants could have wide impact on the disposition of drugs, and may be of consequence especially in relation to commonly used cytotoxics such as docetaxel and doxorubicin.
Previous investigators who studied mainly Caucasian, African American and Dutch populations have identified PXR genetic variants that are generally present at low frequencies in the coding, intronic and the 3 0 -and 5 0 -UTRs. 21, 22 In particular, PXR*4 (4321G4A, R122Q) located in the DNA-binding domain resulted in attenuated activation of a luciferase reporter by rifampicin, 21 and PXR*5 (2904C4T, R98S) in exon 3 that was found in Japanese was associated with reduced CYP3A4 activation in HepG2 cell lines. 23 These potentially functional variants were not found in our study population. In addition, neither the uncommon non-synonymous variant T8555G in exon 8, 22 nor any of the non-synonymous variants reported in Japanese was found in our population. 23 We identified a common variant in the PXR 5 0 -UTR region (À24381 A4C), which showed inter-ethnic variability in allele frequencies, with the C allele being significantly more frequent in Indians (32%) compared to Malays (21) and Chinese (18.5%). This common variant has been reported at varying frequencies in other populations, ranging from 40 to 50% among Caucasians to more than 70% in African Americans. 21, 22 While the frequencies of the variant allele are generally lower in our Asian population, the genotype distribution suggests Chinese and Malays to be genetically more similar, and Indians to be more distinct from these two Asian ethnic groups but closer to Caucasians. From the population genetics viewpoint, this finding is consistent with our previous finding of Indians being genetically distinct from Chinese and Malays but similar to Caucasians with respect to CYP2C9 and VKORC1. 24 The PXR variant, however, did not have an impact on the pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in our population.
CAR appeared to be as well conserved as PXR in our population, with only one common silent variant detected in the coding region that did not have any significant influence on docetaxel and doxorubicin disposition and neutrophil toxicity.
HNF4a is a transcription factor that is involved with the regulation of serum lipid and glucose levels, and multiple polymorphisms have been described with association in type 2 diabetes mellitus and dyslipidemia. 17, 25, 26 HNF4a is expressed in different tissues, and mutated proteins may have wide ranging effects. The HNF4a gene is highly conserved across species, with two activation function domains, AF-1 and AF-2, a DNA-binding domain and a putative ligand-binding domain. We found two non-synonymous single nucleotide polymorphisms (SNPs) in the HNF4a gene. The Met49Val SNP was more common in Indians than Chinese and Malays, and was significantly associated with delayed neutrophil recovery on day 15 of docetaxel chemotherapy, with suggestion of a gene dose effect. This SNP is located at the AF-1 domain and may influence the coactivation by other transcription factors, and therefore interfere with the function of HNF4a. This domain is indispensable for HNF4a function and its absence led to decrease in both the transcriptional potential and interaction with co-activators. [27] [28] [29] [30] The Met49Val SNP may thus interfere with the function of HNF4a and influence the expression of genes involved with cell growth, immune function, amino acid metabolism, lipid and steroid metabolism, cell structure and function, some of which may possibly influence neutrophil recovery. More work is needed to validate the phenotypic associations of this SNP and to determine the functional effects in vitro. Interestingly, this SNP also demonstrated similar inter-ethnic variation, with the variant allele being found more frequently in Indians than in Chinese or Malays. Given the pleiotrophic functions of HNF4a, it would be highly relevant to determine the phenotypic effects of this variant in the context of diseases with inter-ethnic variability. The second SNP Thr130Ile is a rare variant that was previously described, is located in the DNA-binding domain and has been associated with reduced function in hepatocyte cell lines as well as higher incidence of maturity onset diabetes mellitus and lower HDL cholesterol. 25, 31 This SNP was present at a low allele frequency of 1% in our study population; therefore, any potential effect on drug pharmacokinetics or pharmacodynamics could not be determined.
In our previous investigations of common relevant SNPs in CYP3A4 and CYP3A5 and their effects on docetaxel pharmacokinetics and pharmacodynamics, we found no correlation between CYP3A5*3, the most common polymorphism of CYP3A5 that abrogates CYP3A5 hepatic expression, with docetaxel pharmacokinetics. 8 With a larger data set of patients with uniformly favorable performance status and without the confounding factor of previous chemotherapy treatment, we again could not find a correlation between CYP3A5*3 and docetaxel disposition or neutrophil toxicity, confirming our previous finding and that of other investigators on the impact of this SNP. 8, 32 This study is a genotype-phenotype study of the transcriptional regulators of CYP3A4, CYP3A5 and ABCB1 with respect to cytotoxic chemotherapy. PXR, CAR and HNF4a were found to be well conserved in our population, and could not explain the inter-individual variability of docetaxel. However, the limitation of our sequencing approach is that large deletions, insertions and some alternative splicing events of the genes studied will be missed. Other as yet undiscovered genetic factors of docetaxel and doxorubicin disposition and toxicity should be studied further.
Materials and methods

Study population
The primary study population comprised 101 female patients with histologically or cytologically proven locally advanced or metastatic breast cancer who were receiving primary systemic chemotherapy. All subjects provided written informed consent, and the study protocol was approved by the Institutional Ethics Committee. Subjects were randomized to receive one of two alternating sequences of docetaxel (T) and doxorubicin (A), starting with either docetaxel 75 mg m À2 infused over 1 h or doxorubicin 75 mg m À2 as a slow bolus every 3 weeks for six cycles (T-A-T-A-T-A or A-T-A-T-A-T). Tumor assessments were performed at every cycle with bi-dimensional tumor measurements and using the WHO criteria for tumor response. Full blood count was routinely performed on days 8 and 15 following the first cycle of doxorubicin and docetaxel treatment to document the degree of myelosuppression. Additional full blood counts were performed if the patient is hospitalized for febrile neutropenia. The nadir total white count, neutrophil count and platelet count is the lowest value documented within 21 days of the first cycle of docetaxel or doxorubicin. Treatment-related toxicities were graded using the National Cancer Institute Common Terminology for Adverse Events Version 3.0.
Pharmacokinetic analysis of docetaxel and doxorubicin
Plasma samples were obtained from each subject when they received their first cycle of docetaxel or doxorubicin for measurement of drug concentrations at the following time points for docetaxel: predose, 1, 2, 4, 7, 10 and 24 h; and for doxorubicin: predose, 1, 2, 6, 8, 12 and 24 h, following drug administration. Docetaxel concentrations were measured using an isocratic liquid chromatography/tandem mass spectrometry (LC/MS/MS) method as described previously. 33 All plasma concentrations of doxorubicin and its major metabolite doxorubicinol were determined in all samples by reverse-phase HPLC with fluorescence detection using a modification of the method described by Andersen et al. 34 Briefly, 40 ng of daunorubicin was added to 200 ml of plasma samples from each subject as the internal standard. Twenty microliters of 40% zinc sulfate solution, 100 ml of methanol and 100 ml of acetonitrile were added to precipitate proteins and the sample was centrifuged at 15 000 g for 5 min. Sixty microliters of supernatant was injected into the HPLC system. Chromatographic separations were performed using Supelcosil LC 18 column (4.6 Â 150 mm, particle size 3 mm) at 40 1C with fluorescence detection at an excitation wavelength of 500 nm and an emission wavelength of 580 nm. The mobile phase consisted of 0.28 M sodium formate buffer (pH 3.55), acetone and isopropanol (72.5:25:2.5, v/v/v).
The limits of quantification for doxorubicin and doxorubicinol were 2 and 1 ng ml À1 , respectively. The calibration curves were linear over a concentration range of 2-200 ng ml À1 for doxorubicin and 1-100 ng ml À1 for doxorubicinol. The average recoveries were greater than 84% for both analytes. For samples with concentrations beyond 200 ng ml À1 of doxorubicin, appropriate dilution of the samples was performed, and the samples re-tested to ensure measured concentrations fall within the linear part of the calibration curve. The intra-and inter-day coefficients of variation were less than 14%. Doxorubicin and docetaxel pharmacokinetic parameters were analyzed with compartmental and non-compartmental methods based on WINONLIN (Pharsight Corp., Cary, NC, USA). The area under the concentration-time curve (AUC) was estimated using the log-linear trapezoidal option and by extrapolation of the terminal curve to infinity including the last three concentration points; clearance, T 1/2 and volume of distribution at steady state were calculated.
Genotyping of PXR, CAR and HNF4a
Ten milliliters of whole blood was collected from each subject, and genomic DNA was extracted from peripheral mononuclear cells using the Gentra DNA Purification Kit (Gentra Systems Inc., Minneapolis, MN, USA). Each exon along with the splice-site junctions from PXR, CAR and HNF4a genes was amplified by PCR from 100 ng of genomic DNA using 0.5 U of DyNAzyme DNA polymerase (Finnzymes, Espoo, Finland), 0.2 mM dNTP (New England Biolabs Inc., Ipswich, MA, USA) and 0.4 mM each of forward and reverse primers. PCR was performed using the Eppendorf Mastercycler (Eppendorf, Westbury, NY, USA), with an initial denaturing step at 92-95 1C for 2 min, followed by 30-35 cycles of denaturing at 92-95 1C for 90 s, annealing at 55.5-67 1C for 30 s and extension at 72 1C for 1 min. A final 10 min extension step at 72 1C was then performed. The PCR products were treated with 2.5 U of exonuclease I and 0.5 U of Shrimp Alkaline Phosphatase (GE Healthcare, Piscataway, NJ, USA) for 30 min at 37 1C to remove unincorporated nucleotides and primers. The reaction was terminated by heating at 80 1C for 15 min. The treated PCR products were then sequenced using BigDye Terminator V3.1 (Applied Biosystems Inc., Foster City, CA, USA) and run on the ABI 3100 automated Sequence Analyzer (Applied Biosystems Inc.), with the forward PCR primer, the reverse PCR primer or an internal primer when appropriate. Any variants identified were confirmed by sequencing both the sense and the antisense strands and by pyrosequencing.
Pyrosequencing
The pyrosequencing PCR reactions were performed using the Eppendorf Mastercycler (Eppendorf, US) in a total reaction volume of 30 ml with 0.5 U of DyNAzyme DNA polymerase (Finnzymes), 0.2 mM dNTP (New England Biolabs Inc.) and 0.4 mM each of forward and reverse primers. For primers that require biotin labeling (PXR exon 1 reverse primer and CAR exon 5 forward primer), a ratio of 1:9 part (10 mM) primer to universal primer stocks was made prior to use. PCR was performed with an initial denaturing step at 95 1C for 4 min, followed by 39 cycles of denaturing at 95 1C for 30 s, annealing at 60 1C for 30 s and extension at 72 1C for 30 s, followed by a final 1 min extension step at 72 1C.
PCR products were incubated with 3 ml of streptavidin magnetic beads (Amersham Pharmacia Biotech, Uppsala, Sweden) and 1 Â binding buffer (10 mM Tris-HCl, 2 M NaCl, 1 mM EDTA, 0.1% Tween 20) for 10 min at 37 1C. This is followed by denaturing the product mix for 5 s in 0.2 M NaOH slution. Washing was performed with annealing buffer (20 mM Tris-acetate, 2 mM magnesium acetate) for 10 s. The single-stranded products were then transferred to the annealing buffer containing 15 pmol of the sequencing primer and incubated for 2 min at 80 1C in a Hybaid Maxi 14 hybridization oven (Thermo Electron, Bellefonte, PA, USA). Pyrosequencing was performed on a PSQ96MA pyrosequencer instrument (Biotage AB, Uppsala, Sweden).
Alignment of sequences
The nucleotide sequences of PXR (GenBank Accession number AF364606), CAR (Accession number U72959-U72969) and HNF4a genes (Accession number Z30425) were retrieved from GenBank, and sequence alignments were performed using the Multiple Sequence Alignment program by Florence Corpet (http://prodes.toulouse.inra.fr/multalin/ multalin.html).
CYP3A5*3 genotyping
A 770 bp amplicon, comprising the full length of CYP3A5 exon 4 and including the CYP3A5*3 variant, was amplified by PCR using 100 ng genomic DNA, 0.2 mM each of forward (5 0 -GAGCACTTGATGATTTACCT) and reverse (5 0 -TATGCC CAGCCTGTAGTTTG) primers, 1 Â PCR buffer, 0.2 mM dNTPs and 1.5 U DNA Taq polymerase (Promega), in a 25 ml reaction volume. PCR was performed with an initial denaturing step at 94 1C for 5 min, followed by 35 cycles of denaturing at 94 1C for 30 s, annealing at 57 1C for 30 s and extension at 72 1C for 1 min. A final extension step at 72 1C for 5 min was then performed. The PCR products were sequenced as described earlier on the ABI 3100 automated Sequence Analyzer (Applied Biosystems Inc.), using the forward or reverse PCR primer as sequencing primer.
Population analysis
Using pyrosequencing, the population frequency of the nuclear receptor genetic variants that were identified in the breast cancer population was determined by studying 287 cancer-free subjects, including 103 Chinese, 111 Malays and 73 Indians.
Statistical analysis
Analysis of genotypes with continuous pharmacokinetic parameters such as docetaxel and doxorubicin clearance, maximum concentration (C max ), AUC, T 1/2 and with posttreatment blood counts and tumor reductions were performed using the Student's t-test or one-way ANOVA with post hoc Dunnett's test as appropriate, with wild-type genotypes as controls. Analysis of ethnic group with continuous parameters was performed using the one-way ANOVA with post hoc Bonferroni test. Comparison with categorical variables such as ethnic group and febrile neutropenia rates was performed using the w 2 test. All statistical analyses were performed using SPSS Version 11.5 (SPSS Inc., Chicago, IL, USA). All genetic variants were tested for departure from Hardy-Weinberg equilibrium for each ethnic group using w 2 test with one degree of freedom.
